SCHEMBL681668

SCHEMBL681668

CC(C)NC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16171239 1.00 MDM2 (0.41)
SCHEMBL18458286 1.00 MDM2 (0.41)
SCHEMBL2600363 1.00 MDM2 (0.41)
Hydrochloric Acid SCHEMBL15847512 0.97
SCHEMBL23487048 0.91 ALDH1A1 (0.45)
SCHEMBL25069713 0.91 ALDH1A1 (0.45)
SCHEMBL18684792 0.90 GAA (0.43)
SCHEMBL104716 0.90
SCHEMBL104342 0.90
SCHEMBL10259802 0.88 EPHX1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4293016-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2023-12-20 EP claimed
WO-2022194265-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND 北京赛特明强医药科技有限公司 2022-09-22 WO claimed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 US disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 WO disclosed
US-20240400564-A1 INHIBITORS OF THE MENIN-MLL INTERACTION SYNDAX PHARMACEUTICALS, INC. 2024-12-05 US disclosed
US-12037323-B2 Uracil derivatives as Mer-AXL inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
WO-2024130065-A1 SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 WO disclosed
CN-115109036-B Quinazoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2024-06-11 CN disclosed
EP-4337203-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Syndax Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
US-11919901-B2 Inhibitors of the menin-MLL interaction SYNDAX PHARMACEUTICALS, INC. (US) 2024-03-05 US disclosed
EP-0945445-B1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARM CO LTD (JP) 2003-09-03 EP disclosed
US-6239131-B1 WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. ZERIA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 US disclosed
CN-1063442-C Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds ZERIA PHARM CO LTD (JP) 2001-03-21 CN disclosed
EP-0945445-A1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-09-29 EP disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
CN-1184471-A Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds ZERIA PHARM CO LTD (JP) 1998-06-10 CN disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
US-4698093-A POST, PRE EMERGENTS MONSANTO COMPANY (US) 1987-10-06 US disclosed
US-4203988-A ANTISECRETORY AGENTS MERCK & CO., INC. (US) 1980-05-20 US disclosed